Royalty Report: Drugs, Biotechnology, Therapeutic – Collection: 7769


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 7


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 7

Primary Industries

  • Drugs
  • Biotechnology
  • Therapeutic
  • Antibody
  • Disease
  • Drug Discovery
  • Cancer

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 7769

License Grant
This Agreement is to sell certain rights, title, and interest in certain antigen targets pertaining to its fully human monoclonal antibodies to an undisclosed third party.
Field of Use
This agreement pertains to the medical industry.

IPSCIO Record ID: 1395

License Grant
Licensor hereby grants, and Licensee hereby accepts, the following licenses

(a) an exclusive, worldwide license, including the right to grant sublicenses, to develop, make, have made, import, use, sell, offer to sell or have sold Licensed Products and related cell lines, including the Sp2/0 Cell Line.

License Property
Licensor has developed a murine monoclonal antibody directed against the CCR5 antigen and designated by Licensee's as “PRO 140”

“Humanized Antibody(ies)” means the humanized form of the Murine Antibody.

“Licensed Product(s)” means products, for any use, incorporating substantially all of the Humanized Antibody or any modification, variant or fragment of the Humanized Antibody containing at least one variable region of the Humanized Antibody.

“Murine Antibody(ies)” means, subject to Section 2.01(b), the murine monoclonal antibody designated as “PRO 140” directed against the Target Antigen.

Field of Use
Licensee shall also evaluate the Humanized Antibody to determine whether such antibody also possesses anti-HIV activity not less than one-third (1/3) that of the Murine Antibody (“Minimum Anti-HIV Activity”) as measured according to an HIV-1 infectivity assay that measures the extent of HIV-l replication.

IPSCIO Record ID: 3851

License Grant
The Licensor granted the Licensee an exclusive, worldwide and non-assignable except as specified license under the invention to test, evaluate and develop  the Licensed Products in the Field of Use.
License Property
Licensed Products shall mean monoclonal antibodies or treatments derived from the invention.

An employee of the Licensor, is the inventor who has submitted the following disclosures, a portion of which constitute the Invention  (i) UA1524, Therapeutic Monoclonal IgA Antibodies to Cryptosporidium Antigens of 500KDa and Less Than 1,000KDa; (ii) UA1525, Anti-GP23 Antigen Monoclonal IgA Antibodies for Treatment of Cryptosporidiosis, G9H4 and H8H2 and (iii) UA1526, Monoclonal IgA Antibody 1B8 Directed to Cryptosporidium 200KDa Antigen.

Field of Use
Field of Use shall mean the use of the invention for regulator-approved human therapeutics in the treatment of Cryptosporidiosis in humans.

IPSCIO Record ID: 280827

License Grant
The Parties are entering a research license and option agreement regarding the generation of human monoclonal antibodies to neurotactin, the Antigen, where the antibodies to the Antigen are generated through the use of certain Licensor technology.

Licensor shall transfer to Licensee the XenoMouse Animals and other materials.

The executed option will provide exclusivity.

License Property
Licensor Materials shall mean, collectively, the XenoMouse Animals and other materials specified and any XenoMouse Animals immunized with the Antigen.

The materials include Forty ( 40) XenoMouseâ„¢ animals;  2 mg human anti- KLH antibody (generated in XenoMouse);  Immunization protocol;  Fusion protocol;  and,  ELISA protocol for screening.

Field of Use
The Field of use is to develop antibody products for an undisclosed antigen in the field of inflammatory disease.
The research collaboration agreement is to generate fully human antibodies to an antigen target in the field of inflammation.

IPSCIO Record ID: 6777

License Grant
The parties desire to enter into a definitive agreement to collaborate to produce fully human monoclonal antibodies to certain antigen targets in order to develop and commercialize genomics-derived, antibody-based products on the terms set forth below.  The Parties have entered into this collaboration to jointly research, develop and commercialize Collaboration Products with respect to Collaboration Targets throughout the Territory as set forth in this Agreement.
License Property
Collaboration Product shall mean any Antibody Product that contains a Collaboration Antibody.
Field of Use
The rights granted apply for the diagnosis, prophylaxis or treatment of human diseases or conditions.

IPSCIO Record ID: 2968

License Grant
The Company sold to the unrelated Licensee, Dynamicâ„¢Cross-Linking LP rights to potential future revenues for targeting cancer based DXLâ„¢ products to be developed with the Company's technologies using two antibodies to be selected by the Licensee.

The Licensee purchased rights to the first antibody on June 6, 2007 and exercised its option for the purchase of rights to the second antibody on February 7, 2008.

Field of Use
The Company is a drug development company focused on commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXLTM) technology. DXLTM  technology seeks to improve the therapeutic potency of existing monoclonal antibody products by increasing the binding to target antigen,  enhancing antibody effector functions and installing new properties into antibodies. The Company is a development stage enterprise and commercial operations have not yet commenced.

IPSCIO Record ID: 29291

License Grant
The Licensor granted a limited, nontransferable, worldwide patent license, without the right to sublicense, to use the Antibodies solely for the purpose of making and selling the Licensee's Products only in the Research Market.
License Property
Licensor owns and controls certain organisms (cell lines) used in the production of monoclonal antibodies. Monoclonal Antibodies to Human Interferongamma; Monoclonal Antibodies to Human Granulocyte Macrophage-Colony Stimulating Factor; Monoclonal Antibodies to Human Tumor Necrosis Factor-alpha.
Field of Use
Licensee wishes to sell products containing the Monoclonal Antibodies for research use only.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.